NCT03819790View on ClinicalTrials.gov

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

PHASE4CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Basal insulin glargine and lixisenatide

Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)

DRUG

Basal insulin Basaglar/Lantus + gliclazide MR

basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD

DRUG

Metformin

Patients can be administered with most tolerant dose of metformin

Trial Locations (3)

L6S 0C9

LMC Brampton, Brampton

Unknown

LMC Etobicoke, Etobicoke

M1R 0B1

LMC Scarborough, Toronto

All Listed Sponsors
lead

LMC Diabetes & Endocrinology Ltd.

OTHER

NCT03819790 - The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Biotech Hunter | Biotech Hunter